Lv5
910 积分 2022-06-07 加入
AML-454 Real-World Use of Azacitidine (AZA) and Venetoclax (VEN) in Acute Myeloid Leukemia (AML) in Frontline and Relapse/Refractory (R/R) Settings: Multicenter Study From French AURAML Group
16小时前
已完结
Preclinical efficacy of a novel cyclin-dependent kinase 9 inhibitor, QHRD107 against acute myeloid leukemia
1天前
已完结
MCL-1 as a potent target for cancer: Recent advancements, structural insights and SAR studies
6天前
已完结
Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National Analysis
6天前
已完结
MDS-537 A Phase I Study of the Myeloid Cell Leukemia 1 (MCL1) Inhibitor Tapotoclax (AMG 176) in Patients With Myelodysplastic Syndromes After Hypomethylating Agent (HMA) Failure
10天前
已关闭
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
13天前
已完结
Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications
13天前
已完结
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial
1个月前
已完结
HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study
1个月前
已完结
皖公网安备34019202002308
